Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

By H. Rubins, S. Robins, D. Collins, David B. Nelson, M. Elam, E. Schaefer, F. Faas, James W. Anderson. Archives of Internal Medicine, 2002

651 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Diabetic dyslipidaemia: from basic research to clinical practice* (2003, result): “Recent data from two intervention trials, Veterans Affairs HDL Intervention Study (VA-HIT) and Diabetes Atherosclerosis Intervention Study (DAIS), using fibrate (VA-HIT, gemfibrozil and DAIS; fenofibrate) compared with placebo have given encouraging results [163, 167].”
Hypertriglyceridemia: its etiology, effects and treatment (2007, background): “mechanism of action of fibrates includes modulation of the activity of peroxisome proliferator–activated receptor-α in the liver, with reduced hepatic secretion of VLDL and increased lipolysis of plasma triglycerides.(37) Fibrates reduce the quantity of small, dense LDL particles and increase HDL-C.”
Dyslipidemia in Obesity: Mechanisms and Potential Targets (2013, neutral): “20 mmol/L [151–155].”
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors (2006, background): “Major clinical studies revealed that these ligands reduce the incidence of cardiovascular events and that their cardioprotective efficacy is higher in dyslipidemic patients with diabetes or hyperinsulinemia, in which the cardiovascular diseases are the major cause of mortality (Steiner et al., 2001;”